Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by George I’ons
George I’ons | MDDI
Home George I’ons George I’ons Head of Product Strategy and Insight, Owen Mumford Pharmaceutical Services George I’ons is currently Head of Product Strategy and Insights at Owen Mumford having worked for the former OEM and now Pharmaceutical Services division of the organization since 2006. His current focus is on deciphering the rapidly changing pharmaceutical and biotech sectors in relation to their needs for combination products.
Reinforcing sharps safety beyond the hospital
By George I’ons, Head of Product Strategy and Insights, Owen Mumford Pharmaceutical Services The combined pressures of staff shortages, lack of funding and an ageing population have propelled the move towards self-administration for patients with chronic diseases, outside traditional healthcare settings. Today, as the pandemic continues to put acute pressure on our hospitals and clinics, this migration of certain lower-risk medical procedures makes even greater financial and practical sense.
COVID-19: A Wake-Up Call for Sustainable Healthcare
Medical waste is a subset of waste that can be contaminated by potentially infectious blood or other bodily fluids, typically generated at healthcare facilities. This is what makes reducing plastic waste and minimizing the carbon footprint of the healthcare sector more difficult than for other industries. Improper disposal of discarded needles, for example, poses a health risk to the public and may expose waste workers to transmissible diseases and needlestick injuries.
COVID-19: A Wake-Up Call for Sustainable Healthcare
Medical waste is a subset of waste that can be contaminated by potentially infectious blood or other bodily fluids, typically generated at healthcare facilities. This is what makes reducing plastic waste and minimizing the carbon footprint of the healthcare sector more difficult than for other industries. Improper disposal of discarded needles, for example, poses a health risk to the public and may expose waste workers to transmissible diseases and needlestick injuries.
Green goals: Optimising end-to-end sustainability for single-use devices
George I’ons, head of product strategy and insights, Owen Mumford Pharmaceutical Services, explains how medical device manufacturers can make single-use device more environmentally friendly. In England, the NHS is responsible for 4% of total carbon footprint, with a significantly higher percentage of plastic waste compared to other industries. Unlike other industries, healthcare waste may be infectious, resulting in only about 5% of NHS plastic waste is being recovered.
Let’s talk sustainability & single-use in the pharma & medical sectors
The World Bank estimates that the healthcare sector makes up approximately 5% of global carbon emissions – to which the European Union contributes significantly. In recent years, however, the sector has witnessed a tangible shift in mentality when it comes to environmental sustainability.
Taking the Long View: Harnessing Product Lifecycle Drives Sustainability in Medical Devices
Environmental protection and credible sustainability are scaling the global social agenda and the corporate world is not standing by. Reducing emissions and waste are now a key part of business strategy across a number of sectors, and pharmaceutical and medical device manufacturers are not excluded. There are in fact, various benefits that can be achieved in addition to compliance with new demands by regulators, hospital systems, governments and consumers to conform to this emerging reality.
MedTech Intelligence Volume 13 Issue 17
EU IVDR - Process, Data, Reporting & Planning The European In Vitro Diagnostic Regulation (EU IVDR) will profoundly affect the global diagnostics market, requiring new procedures, evidence development, documentation, organizational structures, data management, reporting, and a reassessment of legacy portfolios. Preparation will involve strategic thinking and buy-in at the highest levels. Implementation of IVDR is scheduled for May 2022, with no indication that it will be deferred.
A cross-examination of the connected drug delivery device industry
George I’ons - head of Product Strategy and Insights at Owen Mumford Pharmaceutical Services takes a deep dive into the state of the connected drug delivery device industry. The current health crisis highlights the value of migrating some healthcare procedures beyond the confines of the hospital. In some areas, this is already well-developed, notably remote patient monitoring for chronic respiratory conditions and diabetes.
Connecting Drug Delivery115
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies.
Connecting Drug Delivery115
Contact Us Frederick Furness Publishing Ltd The Candlemakers West Street Lewes, BN7 2NZ United Kingdom T: +44 (0) 1273 47 28 28 E: [email protected] Company #: 8348388 (Registered in England) VAT# : GB 153 0432 49 Terms & Conditions | Privacy Policy
CONNECTED DRUG DELIVERY: ACHIEVING OPTIMAL BENEFITS THROUGH SMART COLLABORATION
Citation: I’ons G, “Connected Drug Delivery: Achieving Optimal Benefits Through Smart Collaboration”. ONdrugDelivery, Issue 115 (Dec 2020), pp 49–51. George I’ons discusses the challenges developing connected devices presents to key market stakeholders when it comes to successful rollout and implementation.
UNISAFE® 2.25: SEAMLESSLY TRANSITIONING TO NEW-GENERATION BIOLOGICS
Citation: I’ons G, “Unisafe® 2.25: Seamlessly Transitioning to New-Generation Biologics”. ONdrugDelivery, Issue 113 (Oct 2020), pp 74–76. George I’ons discusses the benefits of subcutaneously administering new drug formulations, and the factors that manufacturers need to consider when designing delivery devices.
Owen Mumford - ONdrugDelivery
Owen Mumford is a medical device manufacturer that develops products for its own brand and custom device solutions for pharmaceutical and diagnostic companies. Owen Mumford provides research, design and manufacturing capabilities for device production.
Drug Delivery & Environmental Sustainability112
Contact Us Frederick Furness Publishing Ltd The Candlemakers West Street Lewes, BN7 2NZ United Kingdom T: +44 (0) 1273 47 28 28 E: [email protected] Company #: 8348388 (Registered in England) VAT# : GB 153 0432 49 Terms & Conditions | Privacy Policy
FROM DESIGN TO DISPOSAL: ACHIEVING SUSTAINABILITY IN MEDICAL DEVICES
Citation: I’ons G, “From Design to Disposal: Achieving Sustainability in Medical Devices”. ONdrugDelivery, Issue 112 (Sep/Oct 2020), pp 62-65. George I’ons discusses the onus on the device design industry to move towards sustainable practices, including what this entails, how it might be achieved and what benefits sustainability may bring.
Self-Administration: What Drug-Delivery Device Manufacturers Should Know
Image by Dmitry Lobanov - Adobe Stock An expert look at issues driving up the demand for self-administration drug-delivery devices that combine pre-filled safety-engineered aspects.
Self-Administration: What Drug-Delivery Device Manufacturers Should Know
Image by Dmitry Lobanov - Adobe Stock An expert look at issues driving up the demand for self-administration drug-delivery devices that combine pre-filled safety-engineered aspects.
Beyond 2020 vision
PHOTO COURTESY OF 3M Skin is a tricky substrate, making the wearable device design process notoriously challenging. The skin of diabetic patients requires even greater attention, as the condition often leads to loss of elasticity, dryness, thickening, and increased susceptibility to infection. Adhesive technology innovations can minimize challenges associated with diabetic devices, such as continuous glucose monitors (CGMs), insulin pumps, blood glucose test strips, and other diabetic devices.
Flexible force testing systems
PHOTO COURTESY OF 3M Skin is a tricky substrate, making the wearable device design process notoriously challenging. The skin of diabetic patients requires even greater attention, as the condition often leads to loss of elasticity, dryness, thickening, and increased susceptibility to infection. Adhesive technology innovations can minimize challenges associated with diabetic devices, such as continuous glucose monitors (CGMs), insulin pumps, blood glucose test strips, and other diabetic devices.
Market impact of safety syringes in hospital and home drug administration
As the demand for safety-syringes increases, the market for pre-filled safety-engineered devices will increase. This article outlines the main drivers behind this growth. Governments and healthcare systems are under growing pressure to remain effective despite staff shortages, lack of funding and overcrowding of their facilities.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with George
Contact George, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack